Yahia Ibrahim Yahia, Nisreen J. Mohammed, Wisam A. Ameen
Hirsutism relatively is a common medical problem and an important influence on about 5-10% of women of reproductive age. Fifty five female shares in the study, seventeen of them did not continue the study, therefore we evaluated 38 females, aged 18-52 years old. In our study we compared pre-treatment and post-treatment for the color of the hairs and the hair removal frequency and the pain during hair removal for four groups which are good response group and moderate response group and mild response group and no response group, by subjective evaluation of all the patients noted a diminished rate of hair growth (fewer times needed for shaving) and a decrement in the density of hairs on the chin area and change in color of the hair but there was no significant difference between groups regarding hair color and there were highly significant difference in hair removal frequency before and after treatment (P<0.001) when we used finasteride cream 1% for 3 months. Six months of topically applied finasteride (0.5%) does not effect on number and thickness of facial hirsutism significantly. Despite lack of objective changes, on questioning, most patients in finastride group perceived a decrease in hair growth with time.
Keywords: Hirsutism; 5-α- dihydrotestosterone; TSH; FH; LH
1. Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med 2005; 353: 2578-88 [PubMed] .
2. Habif TP. Clinical dermatology: A color guide to diagnosis and therapy, 5th edition, chapter 24, Mosby elsevier inc., china: 926-931, 2010.
3. Al-Robaee A, Al-Zolibani A, Al-Shobaili A, Aslam M. Update on hirsutism. Acta Dermatoven APA 2008; 17(3):103-119. [PubMed]
4. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. Journal Clin Endocrinol Metab 2009; 83:3078-3082 [PubMed] .
5. Camacho F, Randall VA, Price VH and eds. Hair and its Disorders. Biology, Pathology and Management. London: Martin Dunitz 2000; 359–67
6. Kahsar-Miller M, Azziz R. Heritability and the risk of developing androgen excess. J Steroid Biochem Mol Biol 1999; 69:261–268[PubMed] .
7. Castello R, Tosi F, Perrone F et al. Outcome of long-term treatment with the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertil Steril 1996; 66:734- 740. [PubMed]
8. Bayram F, U¨ nlu¨ hızarcı K, Keles, Timur F. Potential utility of insulin sensitizers in the treatment of patients with polycystic ovary syndrome. Treatments in Endocrinology 2002; 1 45–53. [PubMed]
9. Rittmaster RS. Hirsutism. Lancet 1997; 349:191–195. [PubMed]
10. Sahin Y, Dilber S, Kelestimur F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertile steril 2001; 75(3):496-500. [PubMed]
11. Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2000; 85:89–94. [PubMed]
12. Mu¨ derris II, Bayram F, Sahin Y, et al. The efficacy of 250 mg/day flutamide in the treatment of patients with hirsutism. Fertility and Sterility 1996; 66:220–222. [PubMed]
13. Conn JJ, Jacobs HS. The clinical management of hirsutism. European Journal of Endocrinology 1997; 136 339–348. [PubMed]
14. Iraji F, Karbasioun S, Aminorroaya A. Topical Finasteride in Hirsutism: A Double Blind Randomized Clinical Trial on Adult Women. JRMS 2005; 10(6):337-342.
15. Heydari I, Amiri A, Razmjou S, Seyfodin. The Efficacy of Topical Finasteride in the treatment of idiopathic hirsutism. J Turk Acad Dermatol 2008; 2(2):jtad82201a. [Abstract/Full-Text]
16. Faloia E, Filipponi S, Mancini V, Di Marco S, Mantero F. Effect of finasteride in idiopathic hirsutism. J Endocrinol Invest 1998; 21:694-698. [PubMed]
17. Falsetti L, Gambera A, Legrenzi L, Iacobello C, Bugari G. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol 1999;141(4):361-7. [PubMed]
18. Kelestimur F, Everest H, Unluhizarci K, et al. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Eur J Endocrinol 2004; 150:351–4. [PubMed]
19. Bayram F, Müderris II, Guven M, Keles F. Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism. European Journal of Endocrinology 2002; 147:467–471. [Abstract/Full-Text]
Thank you for visiting American Journal of BioMedicine. * = Required fields
[gravityform id=”6″ name=”Feedback”]